Develop DNDI-6174 as a new chemical entity for the treatment of visceral leishmaniasis with the aim of bringing an additional entity with a novel mechanism of action to the visceral leishmaniasis portfolio; and potentially for the treatment of cutaneous leishmaniasis
current phase of drug development
updated 1 Mar 2022
Emerging from the leishmaniasis L205 lead optimization series after showing great efficacy in vivo in both mouse and hamster models for visceral leishmaniasis, DNDI-6174 was nominated as a pre-clinical candidate for visceral leishmaniasis in 2019. DNDI-6174 presents a new mode of action among compounds in DNDi’s leishmaniasis portfolio, as well as a predicted low human dose and a very promising safety margin.
Get our latest news, personal stories, research articles, and job opportunities.